Kornitzer Capital Management Inc. KS Has $4.34 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Kornitzer Capital Management Inc. KS grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 45.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 55,752 shares of the medical device company’s stock after purchasing an additional 17,435 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in DexCom were worth $4,336,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter valued at about $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth about $38,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom during the third quarter worth about $57,000. Covestor Ltd raised its position in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after acquiring an additional 265 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DXCM. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Citigroup raised their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. raised their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Canaccord Genuity Group lifted their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

DexCom Trading Up 1.6 %

NASDAQ DXCM opened at $90.53 on Wednesday. The company has a market cap of $35.36 billion, a price-to-earnings ratio of 54.21, a P/E/G ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50 day moving average price of $82.65 and a 200-day moving average price of $75.62. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 over the last quarter. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.